These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: O-2'-hydroxypropyltrimethyl ammonium chloride chitosan nanoparticles for the delivery of live Newcastle disease vaccine.
    Author: Dai C, Kang H, Yang W, Sun J, Liu C, Cheng G, Rong G, Wang X, Wang X, Jin Z, Zhao K.
    Journal: Carbohydr Polym; 2015 Oct 05; 130():280-9. PubMed ID: 26076628.
    Abstract:
    A novel complex chitosan derivative, O-2'-hydroxypropyltrimethyl ammonium chloride chitosan (O-2'-HACC), was synthesized and used to make nanoparticles as a delivery vehicle for live attenuated Newcastle disease vaccine. We found that O-2'-HACC had high antimicrobial activity, low toxicity, and a high safety level. Newcastle disease virus (NDV) was then encapsulated in the O-2'-HACC nanoparticles (NDV/La Sota-O-2'-HACC-NPs) by the ionic crosslinking method, and the properties of the resulting nanoparticles were determined by transmission electron microscopy, Zeta potential analysis, Fourier transform infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, and X-ray diffraction. NDV/La Sota-O-2'-HACC-NPs had regular spherical morphologies and high stability, with an encapsulation efficiency of 95.68 ± 2.2% and a loading capacity of 58.75 ± 4.03%. An in vitro release assay indicated that release of NDV from NDV/La Sota-O-2'-HACC-NPs occurred slowly. Specific pathogen-free chickens immunized with NDV/La Sota-O-2'-HACC-NPs intranasally had much stronger cellular, humoral and mucosal immune responses than did those immunized intramuscularly or with live attenuated Newcastle disease vaccine. NDV/La Sota-O-2'-HACC-NPs are a novel drug delivery carrier with immense potential in medical applications.
    [Abstract] [Full Text] [Related] [New Search]